Compounds > valine

valine and Brain Vascular Disorders

valine has been researched along with Brain Vascular Disorders in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (44.44)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T1
Angeli, F; Reboldi, G; Verdecchia, P1
Hattori, H; Ito, D; Murata, M; Saito, I; Suzuki, N; Tanahashi, N; Watanabe, K1
Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM1
Bickers, MV; Braun, DL; Johnson, MP; Markgraf, CG1
Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S1
Bannan, S; Carter, A; Catto, AJ; Grant, PJ; Kohler, HP; Stickland, M1
Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ1
Corral, J; Díaz Ortuño, A; González-Conejero, R; Iniesta, JA; Martínez Navarro, ML; Vicente, V1

Trials

1 trial(s) available for valine and Brain Vascular Disorders

ArticleYear
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Clinical therapeutics, 2005, Volume: 27, Issue:5

    Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan

2005

Other Studies

8 other study(ies) available for valine and Brain Vascular Disorders

ArticleYear
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Hypertension and the J-curve phenomenon: implications for tight blood pressure control.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan

2013
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease.
    Neuroscience letters, 2005, Feb-10, Volume: 374, Issue:2

    Topics: Case-Control Studies; Cerebrovascular Disorders; Confidence Intervals; CX3C Chemokine Receptor 1; Female; Gene Frequency; Genotype; Humans; Isoleucine; Male; Membrane Proteins; Methionine; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Receptors, Chemokine; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Threonine; Valine

2005
Behavioral recovery patterns in rats receiving the NMDA receptor antagonist MDL 100,453 immediately post-stroke.
    Pharmacology, biochemistry, and behavior, 1997, Volume: 56, Issue:3

    Topics: Animals; Arterial Occlusive Diseases; Behavior, Animal; Cerebral Arteries; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Grooming; Male; Maze Learning; Neuroprotective Agents; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Time Factors; Valine

1997
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

1997
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
    Stroke, 1998, Volume: 29, Issue:4

    Topics: Aged; Amino Acid Substitution; Case-Control Studies; Cerebral Hemorrhage; Cerebrovascular Disorders; Factor XIII; Female; Genotype; Humans; Leucine; Male; Phenotype; Point Mutation; Polymorphism, Single-Stranded Conformational; Valine

1998
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1998, Volume: 20, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan

1998
Role of factor XIII Val 34 Leu polymorphism in patients with migraine.
    Cephalalgia : an international journal of headache, 2001, Volume: 21, Issue:8

    Topics: Adult; Aged; Cerebrovascular Disorders; Factor XIII; Female; Genotype; Humans; Leucine; Male; Middle Aged; Migraine Disorders; Polymerase Chain Reaction; Polymorphism, Genetic; Valine

2001